Recombinant FSH in alternative doses or versus urinary gonadotrophins for ovulation induction in subfertility associated with polycystic ovary syndrome

Abstract

References Coelingh Bennink HJ, Fauser BC and Out HJ (1998) Recombinant follicle-stimulating hormone (FSH; Puregon) is more ef®cient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. European Puregon Collaborative Anovulation Study Group. Fertil Steril 69,19±25. Loumaye E, Martineau I, Piazzi A, O'Dea L, Ince S, Howles C, Decosterd G, Van Loon K and Galazka A (1996) Clinical assessment of human gonadotrophins produced by recombinant DNA technology. Hum Reprod 11,95±107. van Wely M, Bayram N and van der Veen F (2003) Recombinant FSH in alternative doses or versus urinary gonadotrophins for ovulation induction in subfertility associated with polycystic ovary syndrome: a systematic review based on a Cochrane review. Hum Reprod 18,1143±1149. Yarali H, Bukulmez O and Gurgan T (1999) Urinary follicle-stimulating hormone (FSH) versus recombinant FSH in clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective randomized study. We would like to thank Dr Lass for pointing out a possibly confusing element in our manuscript (van Wely et al., 2003). Although the title of the manuscript states that we compared recombinant FSH (rFSH) with urinary gonadotrophins, in the manuscript we only describe the comparison of rFSH versus urinary FSH (uFSH). Still, the purpose of our Cochrane Review had been to compare rFSH both with uFSH and with HMG. We only analysed and presented results on the comparison of rFSH versus uFSH because there are, at the moment, no studies comparing rFSH with HMG in ovulation induction in women with polycystic ovary syndrome, as Dr Lass rightly states. In the next update of our Cochrane review in the Cochrane library we will state clearly the eligible comparisons.